Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Ruth Bochat

Nurse Practitioner, Family Port Jefferson Station, NY Nurse Practitioner

NPI 1124618228 CMS profile 11176747

1 Jarvin Rd, Port Jefferson Station, NY 11776

Open in the dashboard

General payments

$22,615

318 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Ruth Bochat of Port Jefferson Station, NY is reported in the CMS Open Payments database as having received $22,615 across 318 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Nurse Practitioner, Family profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $6,066 77
2024 General $7,247 112
2023 General $5,299 76
2022 General $3,917 49
2021 General $87 4

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Ruth Bochat
  • Nurse Practitioner, Family median
  • Middle half of Nurse Practitioner, Family
  • National median

In program year 2025, general payments to Ruth Bochat were reported at $6,066. Among 107,232 Nurse Practitioner, Family profiles paid that year, the median was $168 and the middle half received between $53 and $521.

Show as a table
Year Ruth Bochat Nurse Practitioner, Family median Middle half National median
2019 $0 $39 $18–$91 $163
2020 $0 $32 $17–$76 $114
2021 $87 $124 $35–$379 $132
2022 $3,917 $141 $44–$430 $149
2023 $5,299 $154 $49–$476 $160
2024 $7,247 $165 $51–$504 $164
2025 $6,066 $168 $53–$521 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Boston Scientific Corporation $6,380 111 payments
  2. MML US, Inc. $4,780 69 payments
  3. Relievant Medsystems, Inc. $2,691 33 payments
  4. Saluda Medical Americas, Inc. $2,017 11 payments
  5. Nalu Medical, Inc. $1,735 13 payments
  6. Foundation Fusion Solutions, LLC $1,350 9 payments
  7. Abbott Laboratories $967 14 payments
  8. Nevro Corp. $321 8 payments
  9. Medtronic, Inc. $306 5 payments
  10. BIOTRONIK NRO, Inc. $220 3 payments
  11. Other $1,849 42 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $15,302 293 payments
  2. Travel and Lodging $6,500 18 payments
  3. Consulting Fee $690 5 payments
  4. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $90 1 payment
  5. Entertainment $33 1 payment
Products named General payments · program years 2021–2025
  1. ReActiv8 $4,780 69 payments
  2. Intracept Pain $2,816 36 payments
  3. Intracept Pain $2,059 28 payments
  4. Intracept Pain $2,059 28 payments
  5. Intracept Pain $2,059 28 payments
  6. Evoke $2,017 11 payments
  7. Nalu Neurostimulation System $1,735 13 payments
  8. WaveWriter Alpha Prime 16 $1,164 7 payments
  9. Intracept Contains (1)Intracept RF Probe (2)Intracept Access Instruments_NMOD $1,047 28 payments
  10. Intracept Pain $632 5 payments
  11. Other $4,508 95 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 13 drugs

Part D claims

438

Median for Pain Management: 951

Drug cost

$23,063

Median for Pain Management: $26,034

Branded share of claims

29.5%

Median for Pain Management: 29.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Xtampza Er Oxycodone Myristate Brand 17 $9,263
Movantik Naloxegol Oxalate Brand 19 $7,762
Oxycodone Hcl Generic 52 $1,162
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 42 $1,098
Gabapentin Generic 77 $785
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 51 $772
Pregabalin Generic 27 $683
Tramadol Hcl Generic 48 $648
Baclofen Generic 26 $522
Tizanidine Hcl Generic 20 $127

The 10 drugs with the highest cost, of 13 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,732 Part D prescribers listed as Pain Management; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 10 billing codes

Paid by Medicare

$7,092

Medicare's payments for the services billed

Medicare patients

52

Average age 74

Services billed

75

33 women, 19 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Ischemic heart disease 38%
Diabetes 29%
Depression 29%
Osteoporosis 27%
COPD 21%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

2 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
QULIPTA
  • AbbVie, Inc. $9
$9 — —
BOTOX
  • AbbVie, Inc. $9
$9 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

318 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Family in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record